CHARTER OF THE AUDIT COMMITTEE OF THE BOARD OF DIRECTORS OF VIRAX BIOLABS GROUP LIMITED (Conditionally adopted by a board resolution dated

CHARTER OF THE AUDIT COMMITTEE

OF THE BOARD OF DIRECTORS OF

VIRAX BIOLABS GROUP LIMITED

(Conditionally adopted by a board resolution dated January 21, 2022 with effect from the effective date of the registration statement of the Company)

The purpose of the Audit Committee of the Board of Directors (the Board ) of Virax Biolabs Group Limited (the Company ) shall be to:

MEMBERSHIP REQUIREMENTS

The Audit Committee members will be appointed by, and will serve at the discretion of, the Board. The Audit Committee will consist of at least three (3) members of the Board. Members of the Audit Committee must meet the following criteria (as well as any additional criteria required by the rules of the NASDAQ Capital Market ( NASDAQ ) and Securities and Exchange Commission (the SEC )):

The Board may designate one (1) member of the Audit Committee as its chairperson. In the absence of that designation, the Audit Committee may designate a chairperson by majority vote of the committee members.

AUTHORITY AND RESPONSIBILITIES

LIMITATION OF AUDIT COMMITTEE'S ROLE

While the Audit Committee has the responsibilities and powers set forth in this Charter, it is not the duty of the Audit Committee to plan or conduct audits or to determine that the Company's financial statements and disclosures are complete, accurate and in accordance with GAAP and applicable rules and regulations. These are the responsibilities of management and the independent auditors.

It is recognized that the members of the Audit Committee are not full-time employees of the Company, that it is not the duty or responsibility of the Audit Committee or its members to conduct field work or other types of auditing or accounting reviews or procedures or to set auditor independence standards, and that each member of the Audit Committee shall be entitled to rely on (i) the

integrity of those persons and organizations within and outside the Company from which the Audit Committee receives information, and (ii) the accuracy of the financial and other information provided to the Audit Committee, in either instance absent actual knowledge to the contrary.